| NAME |
AFFILIATION |
| FOCUS GROUP 2 |
|
| Doaa Ahmed Mohamed |
University of Liverpool |
| Shannon Allen |
USAID |
| Peter Anderson |
University of Colorado |
| Ernest Asante-Appiah |
Merck, Sharpe & Dohme, LLC |
| Mark Baker |
ViiV Healthcare |
| Marc Baum |
Oak Crest Institute of Science |
| Paul Benn |
ViiV HC |
| Matthew Bosse |
Gilead |
| Su-Young Choi |
FDA |
| Robert Choy |
PATH |
| Vivian Cox |
Johnson & Johnson |
| Logan Donaldson |
The Forum for Collaborative Research |
| Anil Gupta |
Calibr-Skaggs at Scripps Research |
| Timothy Hallett |
Imperial College London |
| Walid Heneine |
CDC |
| Timothy Jancel |
FDA |
| Martina Kovarova |
University of North Carolina at Chapel Hill |
| Raphael Landovitz |
UCLA Center for Clinical AIDS Research & Education |
| Randolph Matthews |
Merck & Co, Inc; Medical Director |
| Antoinette Nelson |
USAID |
| Eric Nuermberger |
Johns Hopkins University |
| Simone Perazzolo |
U of Washington |
| Roger Ptak |
NIAID/DAIDS/TRP/DDPRB |
| Richard Scranton |
Lyndra Therapeutics |
| Raju Subramanian |
Gilead Sciences |
| Sijia Tao |
Emory University |
| Ryan Vargo |
Merck |
| John Walker |
Bill & Melinda Gates Foundation |
| Andrew Weber |
ViiV Healthcare |
| Charles Wells |
Bill & Melinda Gates Medical Research Institute |
| Raymond Xu |
Otsuka |
| Mark Marzinke |
JH |
